{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-023339","form_type":"8-K","ticker":"LXEO","cik":"0001907108","company_name":"Lexeo Therapeutics, Inc.","filed_at":"2026-01-27T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.734463+00:00","generated_at":"2026-05-16T07:37:19.245703+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Lexeo appoints COO and CMO; Eric Adler leaves to lead spin-off Myoventive","bullets":["Jose Manuel Otero, former CTO, becomes COO effective Jan 2, 2026; base salary set at $510,000.","Narinder P. Bhalla appointed Chief Medical Officer effective Jan 20, 2026, succeeding Eric Adler.","Eric Adler steps down as executive officer to become CEO of Myoventive, co-founded by Lexeo, Perceptive Xontogeny, and venBio Partners.","Adler remains senior clinical and scientific advisor to Lexeo."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-023339","json":"https://secwatch.observer/filing/0001193125-26-023339.json","markdown":"https://secwatch.observer/filing/0001193125-26-023339.md","text":"https://secwatch.observer/filing/0001193125-26-023339.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1907108/000119312526023339/0001193125-26-023339-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1907108/000119312526023339/lxeo-20260127.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T07:37:19.245703+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}